

University of Dundee

Tolerability of Bisoprolol on Domiciliary Spirometry in COPD

Jabbal, Sunny; Lipworth, Brian J.

Published in:
Lung

DOI:
[10.1007/s00408-017-0061-y](https://doi.org/10.1007/s00408-017-0061-y)

Publication date:
2018

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Jabbal, S., & Lipworth, B. J. (2018). Tolerability of Bisoprolol on Domiciliary Spirometry in COPD. *Lung*, 196(1), 11-14. <https://doi.org/10.1007/s00408-017-0061-y>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Lung

Tolerability of bisoprolol on domiciliary spirometry in COPD

--Manuscript Draft--

Manuscript Number:	LUNG-D-17-00293R1
Full Title:	Tolerability of bisoprolol on domiciliary spirometry in COPD
Article Type:	Brief Report
Keywords:	COPD; spirometry; FEV1; FEV6; beta blocker
Corresponding Author:	Brian Lipworth, MD University of Dundee School of Medicine Dundee, UNITED KINGDOM
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Dundee School of Medicine
Corresponding Author's Secondary Institution:	
First Author:	Sunny Jabbal, MB ChB
First Author Secondary Information:	
Order of Authors:	Sunny Jabbal, MB ChB Brian J Lipworth, MD
Order of Authors Secondary Information:	
Funding Information:	
Abstract:	<p>We investigated if serial domiciliary measures of spirometry were sensitive at detecting subtle effects of beta-2 blockade associated with bisoprolol in (n=17) patients with COPD.</p> <p>After a two week run in on inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA): beclometasone/formoterol 100/6µg, patients' started additional a long acting muscarinic receptor antagonist: (LAMA) Tiotropium 18µg, with concomitant weekly dose titration of bisoprolol: 1.25mg-2.5mg-5mg. After a further week of bisoprolol 5mg, they were stepped back down to (ICS/LABA) for one week.</p> <p>Mean age was 64 years, mean FEV1 52% predicted, and mean FEV1/FVC ratio of 0.46. Compared to baseline am FEV1 of 1.38L (95% CI 1.14-1.61L), both ICS/LABA/LAMA and ICS/LABA in conjunction with bisoprolol showed statistically significant mean falls of 100ml (1.28L, 95% CI 1.03-1.53L), and 120ml respectively (1.26L, 95% CI 1.01-1.51L); equalling and exceeding the MCID of 100ml respectively. These changes were disconnected from symptoms, reliever use and oxygen saturation.</p>

[Click here to view linked References](#)

Tolerability of bisoprolol on domiciliary spirometry in COPD

¹Sunny Jabbal Mb ChB, ¹Brian J. Lipworth MD.

¹Scottish Centre for Respiratory Research, Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, Scotland, DD1 9SY, UK

Address for Correspondence: Dr BJ Lipworth, Scottish Centre for Respiratory Research, Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, Scotland, DD1 9SY, UK Tel: +44 (0)1382 383188 b.j.lipworth@dundee.ac.uk

Abstract:

We investigated if serial domiciliary measures of spirometry were sensitive at detecting subtle effects of beta-2 blockade associated with bisoprolol in (n=17) patients with COPD.

After a two week run in on inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA): beclometasone/formoterol 100/6µg, patients' started additional a long acting muscarinic receptor antagonist: (LAMA) Tiotropium 18µg, with concomitant weekly dose titration of bisoprolol: 1.25mg-2.5mg-5mg. After a further week of bisoprolol 5mg, they were stepped back down to (ICS/LABA) for one week.

Mean age was 64 years, mean FEV₁ 52% predicted, and mean FEV₁/FVC ratio of 0.46. Compared to baseline am FEV₁ of 1.38L (95% CI 1.14-1.61L), both ICS/LABA/LAMA and ICS/LABA in conjunction with bisoprolol showed statistically significant mean falls of 100ml (1.28L, 95% CI 1.03-1.53L), and 120ml respectively (1.26L, 95% CI 1.01-1.51L); equalling and exceeding the MCID of 100ml respectively. These changes were disconnected from symptoms, reliever use and oxygen saturation.

1
2
3
4 53 Introduction:

5
6 54 There is a reluctance to prescribe beta-blocker therapy to patients with COPD and cardiovascular
7
8 55 disease, even with cardioselective drugs, due to concerns of potential bronchoconstriction (1, 2).
9
10 56 Accumulating evidence however, suggests that more commonly used cardioselective agents
11
12 57 such as bisoprolol do not negatively impact upon laboratory based measures of pulmonary
13
14 58 function, such as the forced expiratory volume in 1 second (FEV₁), in patients with COPD (3).

15
16 59 Whether the pulmonary tolerability of beta-blockers is interdependent with concomitant inhaled
17
18 60 therapy, however, is yet to be established. Therefore it is important to dissect out the relative
19
20 61 contribution of long acting beta-2 agonist (LABA) with or without long acting muscarinic receptor
21
22 62 antagonists (LAMA), in terms of bronchoprotection against a small degree of potential beta-2 receptor
23
24 63 antagonism with bisoprolol.

25
26 64 It would seem logical that a high affinity LABA, such as formoterol, would competitively displace
27
28 65 a beta-1 selective beta-receptor antagonist such as bisoprolol, which exhibits weaker binding
29
30 66 affinity for the beta-2 receptor (4). In vivo however, it has previously been demonstrated that
31
32 67 bisoprolol even at a dose of 5mg significantly blunts the beta-2 mediated response to isoprenaline,
33
34 68 albeit to a lesser than non-selective drugs (5). Moreover, as M3 muscarinic receptors are known
35
36 69 to be involved in mediating bronchoconstriction with beta-blockers the addition of LAMA might be
37
38 70 expected to confer additional protection in terms of pulmonary tolerability of bisoprolol in patients
39
40 71 with COPD. In this regard non-selective beta blockers such as carvedilol are not used on a routine
41
42 72 basis for patients with COPD.

43
44 73 Furthermore, given that COPD is characterised by persistent symptoms and airflow limitation, a
45
46 74 conventional spot measure of FEV₁ done in a laboratory setting may not pick up more subtle
47
48 75 adverse effects of bisoprolol as compared to serial domiciliary testing.
49
50 76

51
52
53 77 Methods:

54
55 78 A previous proof of concept study (6) (NCT01656005) prospectively studied patients aged 40-80
56
57 79 years, with GOLD B and C stage COPD, who in brief after a two week run in on inhaled
58
59 80 corticosteroid (ICS) and LABA as beclometasone/formoterol 100/6µg (Fostair, Chiesi,
60
61 81 Manchester, UK) 2 puffs bid, started concomitant weekly dose titration with bisoprolol (1.25mg-
62
63 82 2.5mg-5mg). They were then placed on triple inhaler therapy with ICS/LABA/LAMA as
64
65 83 Fostair with Tiotropium (Spiriva Handihaler, Boehringer Ingelheim, Bracknell, UK) 18µg od for 1

1
2
3
4 84 week ,and then stepped down again to ICS/LABA (Fostair) for a further week. This study was
5
6 85 approved by the East of Scotland Regional Ethics Committee (12/ES/0054), and completed at
7
8 86 Ninewells Hospital, Dundee, UK.

9
10 87 Here we report on unpublished data in a subgroup of 17 patients in which domiciliary
11
12 88 measurements were available, comprising daily FEV₁ and forced expiratory volume in 6 seconds
13
14 89 (FEV₆), an acceptable surrogate for forced vital capacity in COPD (7) ,measured with a Piko-6
15
16 90 digital lung function meter (Nspire ,Hertford ,UK). Patients were issued paper diary cards during
17
18 91 which they noted their daily global symptom score on a scale of 0-3. This represented their overall
19
20 92 COPD symptoms that day and was rated from 0=none, 1=mild, 2=moderate, 3=severe. This
21
22 93 allowed patients to consider their symptoms in context to their daily lives, activities and
23
24 94 environment. Domiciliary resting heart rate and oxygen saturation were also measured, by a pulse
25
26 95 oximeter (Merlin M-Pulse Lite, Merlin Medical, Rhymney, UK). The impact of bisoprolol 5mg OD
27
28 96 was compared while receiving concomitant ICS/LABA/LAMA and ICS/LABA verses pre beta-
29
30 97 blocker baseline (while taking ICS/LABA).

31
32 98 We analysed the last 4 days of values (which were time averaged) prior to taking bisoprolol
33
34 99 (baseline) as well as while taking bisoprolol with either dual or triple inhaled therapy. These were
35
36 100 then compared using repeated measures ANOVA with post hoc Bonferroni correction to obviate
37
38 101 confounding the overall alpha error by multiple pairwise comparisons (P<0.05 two tailed) .

39 102 Results:

40
41 103 80% of the patients were male, with a mean age of 64 years, mean FEV₁ 52% predicted, mean
42
43 104 FEV₁/FVC ratio of 0.46, mean 50 pack year smoking history, and 7% mean FEV₁ reversibility to
44
45 105 salbutamol 400µg. Results are presented in table 1. Compared to baseline, both ICS/LABA/LAMA
46
47 106 and ICS/LABA in conjunction with bisoprolol were associated in similar mean falls in morning
48
49 107 domiciliary FEV₁, amounting to means of 100ml and 120ml respectively. There was no statistically
50
51 108 significant difference between ICS/LABA/LAMA and ICS/LABA while taking bisoprolol for either
52
53 109 FEV₁ or FEV₆. Despite bisoprolol producing a mean domiciliary heart reduction of 11 beats/min,
54
55 110 there was no significant decline in oxygen saturation compared to baseline. Moreover the mean
56
57 111 symptom score did not change while taking bisoprolol, remaining at a mild level. There was also
58
59 112 no significant difference in reliever use with salbutamol pre or post beta blocker. We observed no
60
61 113 significant correlation between either peripheral blood eosinophil count (mean 215 (95%CI 154-
62
63 114 275) cells/µl) or reversibility to salbutamol and percentage fall in domiciliary FEV₁ or FEV₆ whilst
64
65 115 taking bisoprolol (figure).

Discussion

Our results showed that the effect of bisoprolol on domiciliary morning FEV₁ was not only statistically significant but also equalled (with ICS/LABA/LAMA) or exceeded (with ICS/LABA) the minimal clinically important difference value of 100ml (8) . We were surprised to find such an effect as we previously did not detect any significant impact on laboratory spot FEV₁ measurement with bisoprolol in conjunction with either dual (mean FEV₁ fall of 10ml) or triple concomitant inhaler therapy (mean FEV₁ increase of 30ml) . This illustrates the superior sensitivity of measuring serial domiciliary lung function for detecting more subtle changes associated with bisoprolol in COPD. However despite the reductions in FEV₁ and corroborating reduction in resting heart rate (due to beta-1 blockade) , there was no associated change in either salbutamol use, symptom score or oxygen saturation. This in turn infers there is a disconnect between FEV₁ and FEV₆ from either symptoms or gas exchange. The corollary being that a small decline in lung function may have little real life impact on patients being prescribed beta blocker therapy. Alternatively another viewpoint may be that lowering resting heart rate resulted in patients experiencing less dyspnoea throughout the day. Our study demonstrated a reduction in resting heart rate from 80 bpm to 69 bpm after bisoprolol; COPD patients with heart rates <75 bpm have a decreased cardiovascular mortality versus those with a heart rate ≥75 (9).

Bisoprolol is highly selective with a 14:1 ratio for β₁ to β₂ receptor affinity (10). However it is well recognised that although there may be dose related airways related beta-2 blockade with cardioselective drugs ,it is still considerably less than with non selective agents (11). In terms of trying to identify the potential impact of an asthmatic component of COPD on beta-2 blockade with bisoprolol, we did not observe any relationship of FEV₁ fall to blood eosinophils or salbutamol reversibility.

The failure of concomitant tiotropium as inhaled triple therapy to confer protection against bronchoconstriction with bisoprolol was surprising. However we appreciate that we did not have a baseline value for comparison while taking ICS/LABA/LAMA to assess the relative bronchodilator impact of tiotropium in the absence of bisoprolol. Another limitation of this proof of concept study is the small sample size, and that there was no placebo arm to compare with bisoprolol but only a baseline value while taking ICS/LABA. Finally, our study duration was not sufficiently long enough to assess the impact of beta blocker therapy on exacerbations.

In summary our study demonstrates that in the context of single or dual long acting bronchodilator therapy , the beta-1 selective antagonist bisoprolol was associated with subtle but significant

falls in domiciliary FEV₁ ,which were disconnected from symptoms ,reliever use and oxygen saturation. Trials are now underway in COPD to evaluate the effects of bisoprolol on cardiopulmonary exercise testing (ClinicalTrials.gov NCT02380053) as well as to assess the impact on COPD exacerbations.

Figure Legend:

Correlation of percentage change in forced expiratory volume in one second (FEV₁: top), and in six seconds (FEV₆ bottom), and eosinophil counts. P=ns, no relationship observed.

Conflict of Interest: Dr. Jabbar reports personal fees and non-financial support from Chiesi Pharma, personal fees and non-financial support from Pfizer, non-financial support and other from Napp, personal fees and non-financial support from AstraZeneca, personal fees from Boehringer Ingelheim, non-financial support from TEVA, outside the submitted work. Dr. Lipworth reports grants, personal fees and non-financial support from Chiesi, grants, personal fees, non-financial support and other from Boehringer Ingelheim, grants and personal fees from Meda , grants, personal fees and non-financial support from Teva , grants from Janssen, grants from AstraZeneca, grants from Roche, personal fees from Dr Reddys , personal fees from Cipla, personal fees from Lupin, personal fees from Sandoz, grants from Sanofi , outside the submitted work.

References

1. Lipworth B, Skinner D, Devereux G, Thomas V, Ling Zhi Jie J, Martin J, et al. Underuse of beta-blockers in heart failure and chronic obstructive pulmonary disease. *Heart (British Cardiac Society)*. 2016 Dec 01;102(23):1909-14.
2. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. *QJM : monthly journal of the Association of Physicians*. 2005 Jul;98(7):493-7.
3. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. *The Cochrane database of systematic reviews*. 2005 Oct 19(4):Cd003566.
4. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. *Naunyn-Schmiedeberg's archives of pharmacology*. 2004 Feb;369(2):151-9.
5. Lipworth BJ, Irvine NA, McDevitt DG. A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. *European journal of clinical pharmacology*. 1991;40(2):135-9.
6. Jabbal S, Anderson W, Short P, Morrison A, Manoharan A, Lipworth BJ. Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD. *QJM : monthly journal of the Association of Physicians*. 2017.
7. Swanney MP, Jensen RL, Crichton DA, Beckert LE, Cardno LA, Crapo RO. FEV(6) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. *American journal of respiratory and critical care medicine*. 2000 Sep;162(3 Pt 1):917-9.
8. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. *American journal of respiratory and critical care medicine*. 2014 Feb 01;189(3):250-5.
9. Jensen MT, Marott JL, Lange P, Vestbo J, Schnohr P, Nielsen OW, et al. Resting heart rate is a predictor of mortality in COPD. *European Respiratory Journal*. 2013 Aug;42(2):341-9.
10. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. *British journal of pharmacology*. 2005 Feb;144(3):317-22.
11. Lipworth BJ, Brown RA, McDevitt DG. Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade. *Br J Clin Pharmacol*. 1989 Jul;28(1):95-102.





Table 1. Results of domiciliary measures

	BASELINE (OFF BISOPROLOL)	ICS/LABA/LAMA (+BISOPROLOL)	ICS/LABA (+BISOPROLOL)
FEV1 AM (L)	1.38 (1.14- 1.61)	1.28 (1.03- 1.53)*	1.26 (1.01- 1.51)*
FEV1 PM (L)	1.38 (1.12- 1.63)	1.32 (1.06- 1.57)	1.29 (1.04- 1.54)*
FEV6 AM (L)	2.46 (2.06- 2.85)	2.33 (1.90-2.25)	2.27 (1.84-2.69)
FEV6 PM (L)	2.50 (2.12-2.89)	2.39 (1.98- 2.80)	2.33 (1.92-2.74)*
SYMPTOMS AM	0.27 (-0.21- 0.55)	0.28 (-0.48- 0.51)	0.34 (0.10- 0.57)
SYMPTOMS PM	0.28 (-0.08- 0.57)	0.40 (0.16- 0.63)	0.47 (0.17-0.77)
RELIEVER USE AM	0.6 (0.2- 1.3)	0.8 (0.2- 1.7)	1.0 (0.1- 2.0)
RELIEVER USE PM	1.7 (0.2-3.3)	1.5 (0.2-2.8)	1.9 (0.4- 3.4)
HEART RATE (BPM)	80 (74-85)	69 (64-73)*	69 (65-73)*
SP02 (%)	96 (95-97)	95 (94-97)	96 (95-97)

Domiciliary data are presented as means and 95% CI. *P<0.05 vs pre beta-blocker baseline while taking bisoprolol and concomitant ICS/LABA or ICS/LABA/LABA. Reliever use equates to puffs of salbutamol. No difference was observed between ICS/LABA/LAMA and ICS/LABA while taking bisoprolol.